GSK Argentina

Name

GSK Argentina

Legal name

GlaxoSmithKline plc

Website

https://glaxosmithkline.com.ar

Company type

Public

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG)

Keywords

• Biopharmaceutical products
• Vaccines and medicines
• Specialty oncology therapeutics
• Respiratory immunology treatments
• HIV infectious disease therapies

Headquarters

HQ city

Buenos Aires

HQ country

Argentina

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: GSK Argentina generates revenue through the sale of specialty medicines, vaccines, and general medicines across its three business units.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

GSK Argentina researches, develops, manufactures, and distributes specialty medicines, vaccines, and general medicines across four therapeutic areas: respiratory/immunology and inflammation, oncology, HIV, and infectious diseases. The company operates through three business units (General Medicines, Vaccines, and Specialty & Oncology) and invests in clinical research across 200+ research centers in Argentina.

Product overview

GSK Argentina operates as a biopharmaceutical company with three core business units: General Medicines (Medicinas Generales), Vaccines (Vacunas), and Specialty & Oncology (Especialidades y Oncología). The company researches, develops, and produces innovative solutions across four therapeutic areas: respiratory/immunology and inflammation, oncology, HIV, and infectious diseases. In 2024, GSK Argentina invested $25 million in over 60 clinical studies focused on oncology, specialty medicines, and vaccines, involving 200 research centers across the country. The company also maintains a quality control laboratory for vaccines, HIV, Oncology, and prescription medicines (Rx), and operates the Trust in Science program supporting basic scientific research.

Differentiator

Problem solved

Functional benefit

Products and services

• Medicinas Generales (General Medicines) General medicines business unit offering treatments across various conditions, part of GSK Argentina's portfolio alongside Vaccines and Specialty & Oncology. Targets healthcare providers and patients in Argentina.
• Vacunas (Vaccines) Vaccine business unit providing vaccine products developed, tested, and distributed by GSK Argentina, including vaccines for HIV, oncology, and respiratory conditions. Quality control is supported by a dedicated laboratory.
• Especialidades & Oncología (Specialties & Oncology) Specialty medicines and oncology treatments business unit focused on four therapeutic areas: respiratory/immunology and inflammation, oncology, HIV, and infectious diseases. Targets healthcare providers managing complex conditions in Argentina.
• Flovent HFA Authorized Generic (Fluticasone Propionate) Inhaled asthma treatment (fluticasone propionate). The authorized generic version was launched in May 2022 through Prasco in the United States; supplied as part of GSK's respiratory portfolio.

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Trust in Science Program PartnerscoreStrategic or Co-development Partner · 1 January 2011Since 2011, GSK maintains a public-private collaboration and co-funding agreement to support basic scientific research. Key premise is transparency and respect for intellectual property belonging to the researcher and/or institution making the discovery. Investment of $8 million has supported 38+ research projects on diseases of high social priority involving 190 scientists from national reference centers.

Scale indicators8 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Pfizer Argentina: Argentine subsidiary of Pfizer Inc., one of the world's largest biopharmaceutical companies. Directly comparable to GSK Argentina as a multinational pharma operating across vaccines, specialty medicines and oncology with a similar enterprise sales motion and HCP engagement model.
• Novartis Argentina: Argentine subsidiary of Novartis AG, a global biopharma with a comparable therapeutic footprint in oncology, immunology, respiratory and infectious diseases. Operates the same three-pillar model of innovative medicines, generics and clinical R&D in Argentina.
• Roche Argentina: Argentine subsidiary of F. Hoffmann-La Roche, focused on pharmaceuticals and diagnostics. Closely comparable in oncology and specialty care orientation, with similar enterprise sales to HCPs and substantial local clinical research activity.
• Sanofi Argentina: Argentine subsidiary of Sanofi, a major global vaccines competitor (Sanofi Pasteur) and player in specialty and general medicines. Most directly comparable to GSK Argentina on the vaccines franchise, distribution model and HCP engagement.
• Merck Sharp & Dohme (MSD) Argentina: Argentine subsidiary of Merck & Co., a direct peer in oncology, vaccines and specialty pharmaceuticals with a comparable R&D and clinical trials footprint in Argentina and similar reliance on HCP-facing sales.
• Johnson & Johnson Innovative Medicine Argentina: Argentine pharma arm of Johnson & Johnson, operating across oncology, immunology, infectious diseases and pulmonary hypertension. Comparable in specialty/innovative-medicines orientation and HCP engagement strategy.
• AstraZeneca Argentina: Argentine subsidiary of AstraZeneca, comparable in respiratory, oncology and infectious-disease focus. Similar scale and enterprise sales motion targeting HCPs and institutions.
• Boehringer Ingelheim Argentina: Argentine subsidiary of Boehringer Ingelheim, focused on respiratory, oncology and cardiometabolic specialty medicines. Comparable specialty-care go-to-market and limited-but-targeted product portfolio in Argentina.
• Bayer Argentina: Argentine subsidiary of Bayer, operating in pharmaceuticals and consumer health. Comparable in distribution scale, HCP engagement and diversified therapeutic portfolio including women's health and specialty care.
• Takeda Argentina: Argentine subsidiary of Takeda Pharmaceutical, focused on specialty medicines in oncology, rare diseases, gastroenterology and neuroscience. Comparable enterprise sales model and selective therapeutic-area focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GSK Argentina